A novel use for an old drug: The potential for minocycline as anti-HIV adjuvant therapy

Journal of Infectious Diseases

Volumn 201, Issue 8, 2010, Pages 1115-1117

  Copeland, Karen F T ^a   Brooks, James I ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ATAZANAVIR; AZITHROMYCIN; CD45RA ANTIGEN; CD69 ANTIGEN; CD71 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GAMMA INTERFERON; HLA DR3 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRASE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; ROXITHROMYCIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ASTROCYTE; BIOINFORMATICS; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; ENCEPHALITIS; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROPROTECTION; NOTE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS; STROKE; T LYMPHOCYTE ACTIVATION; VIRUS LATENCY; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; CHEMOTHERAPY, ADJUVANT; CYTOKINES; HIV INFECTIONS; HUMANS; MINOCYCLINE;

EID: 77950279225     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651278     Document Type: Note

References (24)

1. + T cells. J Infect Dis 2010;201(8): 1132-1140 (in this issue).
2. Desaki M, Takizawa H, Ohtoshi T, et al. Eryth-romycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000;267: 124-128.
3. Kikuchi T, Hagiwara K, Honda Y, et al. Cla-rithromycin suppresses lipopolysaccharide-in-duced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother 2002;49: 745-755.
4. Lopez-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Phar-macol 2008;8: 286-291.
5. Zink MC, Suryanarayana K, Mankowski JL, et al. High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 1999;73: 10480-10488.
6. O'Dell JR, Blakely KW, Mallek JA, et al. Treat-ment of early seropositive rheumatoid arthri-tis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthri-tis Rheum 2001;44: 2235-2241.
7. Metz LM, Zhang Y, Yeung M, et al. Mino-cycline reduces gadolinium-enhancing mag-netic resonance imaging lesions in multiple sclerosis. Ann Neurol 2004; 55: 756.
8. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an open-label, ev-aluator-blinded study. Neurology 2007; 69: 1404-1410.
9. Rovin BH, Lu L, Saxena R. A novel polymor-phism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999;259: 344-348.
10. Zink MC, Uhrlaub J, DeWitt J, et al. Neu-roprotective, anti-human immunodeficiency virus activity of minocycline. JAMA 2005; 293: 2003-2011.
11. Si Q, Cosenza M, Kim MO, et al. A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia. J Neurovirol 2004;10: 284-292.
12. Jenwitheesuk E, Samudrala R. Identification of potential HIV-1 targets of minocycline. Bioinformatics 2007; 23: 2797-2799.
13. Colovic M, Caccia S. Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J Chro-matogr B Analyt Technol Biomed Life Sci 2003;791: 337-343.
14. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excito-toxicity by inhibiting activation and prolif-eration of microglia. J Neurosci 2001; 21: 2580-2588.
15. Suk K, Lee J, Hur J, et al. Activation-induced cell death of rat astrocytes. Brain Res 2001; 900: 342-347.
16. Sharkey ME, Teo I, Greenough T, et al. Per-sistence of episomal HIV-1 infection inter-mediates in patients on highly active anti-ret-roviral therapy. Nat Med 2000;6: 76-81.
17. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65: 65-70.
18. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on ce-rebrospinal fluid HIV RNA and neurocogni-tive performance. AIDS 2009;23: 1359-1366.
19. DiCenzo R, Peterson DR, Cruttenden K, et al. Effects of minocycline and valproic acid coadministration on atazanavir plasma concent-rations in human immunodeficiency virus-infected adults receiving atazanavir-ritona-vir. Antimicrob Agents Chemother 2008; 52: 3035-3039.
20. Chintu C, Bhat GJ, Walker AS, et al. Co-tri-moxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004;364: 1865-1871.
21. Kulkosky J, Sullivan J, Xu Y, Souder E, Hamer DH, Pomerantz RJ. Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents. AIDS Res Hum Retroviruses 2004;20: 497-505.
22. Lehrman G, Hogue IB, Palmer S, et al. De-pletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366: 549-555.
23. Van Lint C, Quivy V, Demonte D, et al. Molecular mechanisms involved in HIV-1 tran-scriptional latency and reactivation: implica-tions for the development of therapeutic strategies. Bull Mem Acad R Med Belg 2004; 159: 176-189.
24. Yang HC, Xing S, Shan L, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that re-verse latency without cellular activation. J Clin Invest 2009; 119: 3473-3486.